Anti-angiogenic agents such as tyrosine-kinase inhibitors (TKI) and VEGF inhibitors, targeting various pro-angiogenic signaling pathways have been validated to improve survival in advanced HCC (12). Here, VEGFA is linked to hepatocellular carcinoma.